The FDA approved LEQEMBI IQLIK (lecanemab-irmb), a subcutaneous injection that starts treatment for early Alzheimer's at home, on July 13, 2026. Eisai and Biogen announced in the FDA approval notice that the starting dose is 500 mg once weekly as two 250-mg autoinjector shots, with brain MRI checks and ARIA risk review still required. Early Alzheimer's here means mild cognitive impairment or mild dementia due to Alzheimer's disease. Treatment starts only after amyloid-beta pathology is confirmed, so a memory-clinic evaluation comes before any home injection.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Apply through Multivu’s official page — Use this page to review requirements and apply directly.
- Read the official guidance from Ajmc — Use this primary source to verify the official guidance.
Table of Contents
- Who qualifies with mild cognitive impairment?
- What is the main safety risk?
- Which clinic checks still apply at home?
- What supports the starting dose and what comes next?
Who qualifies with mild cognitive impairment?
Adults with mild cognitive impairment or mild dementia due to Alzheimer's disease may qualify. AJMC reported in its approval summary that amyloid-beta pathology must be confirmed before treatment begins.
Ask the care team to confirm each starting condition: Bring a care partner to that visit. The partner can learn the two-shot weekly routine and watch the calendar for scan dates.
- adult diagnosis is mild cognitive impairment or mild dementia due to Alzheimer's
- amyloid-beta pathology is confirmed
- ApoE ε4 status, MRI plan, and ARIA risk were discussed
What is the main safety risk?
LEQEMBI IQLIK carries an FDA boxed warning for amyloid-related imaging abnormalities with edema (ARIA-E) and hemosiderin deposition (ARIA-H). Practical Neurology noted in its safety report that ARIA-H includes microhemorrhage and superficial siderosis that can be serious or fatal. Risk is higher for ApoE ε4 homozygotes, about 15% of Alzheimer's patients.
FDA prescribing information says these patients face higher rates of symptomatic, serious, and severe ARIA. Prescribers should test for ApoE ε4 status before initiation. Use that result to discuss genotype-specific risk and decide whether to start.
Which clinic checks still apply at home?
Home injections do not remove clinic monitoring. Eisai and Biogen stated via PR Newswire in the availability announcement that brain MRI is required before starting treatment and at specified time points afterward. Most ARIA-E events occurred within the first seven doses.
ARIA can still occur at any time during treatment. Each weekly dose uses two consecutive 250-mg autoinjectors, each given in about 15 seconds by the patient or care partner. Keep MRI appointments even when injections feel routine, and report new neurologic changes promptly.
What supports the starting dose and what comes next?
FDA based initiation approval on IV efficacy trials Study 201 and Clarity AD plus open-label extension data. AJMC reports that weekly subcutaneous exposure equals IV exposure, with similar amyloid removal and no increase in isolated ARIA-H versus placebo. Initiation-dose autoinjectors became available in the U.S.
in late August 2026 through specialty pharmacy, according to Eisai and Biogen. Ask the prescribing clinic which specialty pharmacy stocks the initiation cartons. After 18 months, patients may continue at 360 mg weekly or switch between IV and subcutaneous forms. Confirm the long-term plan before the first home dose so refills, scans, and visits stay aligned.
You Might Also Like
- FDA’s 2026 At-Home Leqembi IQLIK Starting Dose: Questions People With Mild Cognitive Impairment Can Ask an Alzheimer’s Specialist
- The WHO 45% Modifiable Dementia Risk Estimate in 2026: Questions Adults Over 65 Can Discuss With a Clinician
- Maine’s 2026 ECHO Training for Dementia Risk Reduction: What the News Means for Adults in Midlife
